With GSK kicking its research and development engine into high gear in recent years, a shuffling of the scientific priorities ...

Britain's life sciences sector plan receives a mixed reception from the pharmaceutical industry. While the strategy aims to boost R&D, industry leaders criticize the lack of resolution on drug pricing ...

Executives who treat capital allocation as a CEO-level strategic discipline are best positioned to thrive in a volatile and ...

Britain launched a life sciences sector plan on Wednesday to a mixed response from the pharmaceutical industry, which welcomed proposals to boost R&D but warned it would fail to keep firms competitive ...

With the aim of being the largest life sector by 2035 behind only the US and China, the UK government is ramping up commercialisation.

Allergy care market grows with rising allergy cases, biologic innovations, and demand for personalized, accessible treatment solutions wor ...

While Novartis holds a diversified product portfolio, there is some product concentration with its largest drugs, Entresto (close to 15% of sales) and Cosentyx (close to 10% of sales). Both drugs will ...

GSK's business development team have been working overtime of late, with three R&D deals announced in the last few days across Alzheimer's disease and cancer. The Alzheimer's agreement – with ...

As biopharma innovation becomes increasingly data-driven and autonomous, the integration of Chinese AI- renowned for rapid ...

Overview of Hepatitis C Drug MarketThe global Hepatitis C Drug Market is valued at USD 7.95 Billion in 2024 and is projected ...

Market OverviewThe global Epilepsy Drugs Market is valued at USD 10.63 billion in 2024 and is projected to reach a value ...

The motor neuron disease treatment market is witnessing substantial growth, primarily fueled by the rising incidence of conditions like Amyotrophic L ...